Scholar Rock Holding Corp. SRRK

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.

Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular

CAMBRIDGE, Mass., September 21, 2026--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hired employees, consisting of inducement stock options to purchase an aggregate of 23,801 shares of common stock and inducement restricted stock units, covering an aggregate of 59,301 shares of its common stock.

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.

Scholar Rock Holding Corporation (NASDAQ:SRRK) secured FDA approval on September 11 for ISEMBYLD, apitegromab-mstn, to treat spinal muscular atrophy in adults and children aged two and older currently receiving survival motor neuron 2 (SMN2)-targeted therapy. Approval opens a commercial opportunity built around adding muscle-directed treatment to existing care. The investment question now shifts to how […]

Scholar Rock Holding now carries a slightly higher modelled fair value, shifting from US$59.31 to US$62.06. This places it in line with the low to mid US$60s price targets cited in recent research. Street commentary around the Isembyld approval, updated adoption assumptions and the US$63 JPMorgan target helps explain why analysts are comfortable anchoring expectations around this new level. As you read on, you will see how these evolving targets and the surrounding narrative might shape your...

Scholar Rock (SRRK) could face some friction during the early commercialization of Isembyld after th

The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older. The decision makes ISEMBYLD the first muscle-targeted therapy to demonstrate motor...

On a call on Monday, the company set a list price of $11,659 per vial of Isembyld, or about $310,000 a year for a typical patient.

Scholar Rock Holding (SRRK) won early regulatory approval of Isembyld to treat spinal muscular atrop

Scholar Rock Holding Corp (NASDAQ:SRRK) shares rose 9. 1% in pre-market trading to $60.

Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology.

Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.

FDA approved Isembyld for patients age two and older who already take certain spinal muscular atrophy drugs.

CAMBRIDGE, Mass., September 11, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targete

CAMBRIDGE, Mass., September 02, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with FSHD. In addition, the Company announced that participant dosing is underway in the Phase 2 FORGE

CAMBRIDGE, Mass., August 27, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences: